<unk>  (trade name Roctavian, also known as BMN-270 and Valrox) is an experimental gene therapy for hemophilia A under development by BioMarin Pharmaceutical.
Valoctocogene roxaparvovec
Alipogene tiparvovec
Enadenotucirev
Neo-Viagra-Y.R.
Onasemnogene abeparvovec
Belantamab mafodotin
Atoltivimab/maftivimab/odesivimab
Sacituzumab govitecan